Afuco™ Anti-Human CGRP ADCC Recombinant Antibody (ALD403), ADCC Enhanced (CAT#: AFC-153CL)

Figure 1 Haemodynamic data from a 14 week, repeat dose study of TEV-48125 (LBR-101) in monkeys.

Data are shown with 95% confidence intervals. A: systolic blood pressure; B: diastolic blood pressure; C: heart rate; D: time–concentration profile at weeks 1 and 13. Modified from reference 73. Vehicle, 10 mg kg–1, 100 mg kg–1, 300 mg kg–1. Week 1 10 mg kg–1, 100 mg kg–1, 300 mg kg–1, Week 13 10 mg kg–1, 100 mg kg–1, 300 mg kg–1

Bigal,M.E.,Walter,S.,&Rapoport,A.M.(2015).Therapeutic antibodies against CGRP or its receptor. British journal of clinical pharmacology, 79(6), 886-895.

Figure 2 Cardiovascular parameters in subjects receiving TEV-48125 (LBR-10) or placebo.

Data from phase 1 study of TEV-48125 in normal, healthy women volunteers. TEV-48125 or placebo was delivered as a 1 h i.v. infusion. Means are shown ± SD. placebo, LBR-10

Bigal,M.E.,Walter,S.,&Rapoport,A.M.(2015).Therapeutic antibodies against CGRP or its receptor. British journal of clinical pharmacology, 79(6), 886-895.

Figure 3 Free ALD403 (Mean±SD).

Bigal,M.E.,Walter,S.,&Rapoport,A.M.(2015).Therapeutic antibodies against CGRP or its receptor. British journal of clinical pharmacology, 79(6), 886-895.

Figure 4 Cmax (Mean±SD) vs. Dose following IV Infusion of ALD403.

Bigal,M.E.,Walter,S.,&Rapoport,A.M.(2015).Therapeutic antibodies against CGRP or its receptor. British journal of clinical pharmacology, 79(6), 886-895.

Figure 5 AUC(0-T) (Mean±SD) vs.Dose following IV Infusion of ALD403.

Bigal,M.E.,Walter,S.,&Rapoport,A.M.(2015).Therapeutic antibodies against CGRP or its receptor. British journal of clinical pharmacology, 79(6), 886-895.

Figure 6 Mean±SEM Change from Baseline for Blood Perfusio nRatio following Topical Capsaicin Challenge.

Following a single IV infusion of 30 to 1000 mg, ALD403 had an effect on reducing the dermal vasodilation inducted by topical treatment with capsaicin relative to placebo that was generally dose dependent and persistent through week 12

Bigal,M.E.,Walter,S.,&Rapoport,A.M.(2015).Therapeutic antibodies against CGRP or its receptor. British journal of clinical pharmacology, 79(6), 886-895.

Figure 7 ALD403 100 mg IV vs.100 mg SC.

The PD response following 100 mg SC ALD403 SC was similar to 100 mg IV ALD403

Bigal,M.E.,Walter,S.,&Rapoport,A.M.(2015).Therapeutic antibodies against CGRP or its receptor. British journal of clinical pharmacology, 79(6), 886-895.